Sutro Biopharma (Sutro Biopharma) Total Current Liabilities : $79.5 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Sutro Biopharma's total current liabilities for the quarter that ended in Mar. 2024 was $79.5

Sutro Biopharma Total Current Liabilities Historical Data

The historical data trend for Sutro Biopharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Total Current Liabilities Chart

Sutro Biopharma Annual Data

Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 32.97 29.60 41.74 66.55 93.75

Sutro Biopharma Quarterly Data

Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24

Total Current Liabilities Get a 7-Day Free Trial 59.49 67.13 73.61 93.75 79.51

Sutro Biopharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Sutro Biopharma's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 44.016 + 10.481

+ Other Current Liabilities + Current Deferred Liabilities

= 18.583 + 20.666

= 93.7

Sutro Biopharma's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 41.85 + 6.673

+ Other Current Liabilities + Current Deferred Liabilities

= 10.484 + 20.502

= 79.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Sutro Biopharma Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Sutro Biopharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma (Sutro Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (NAS:STRO) » Definitions » Total Current Liabilities

Comparable Companies

ZVRA VSTM APLT STOK GLUE ALLK AKBA LYRA ATNM CYDY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

S09:Germany S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Executives

Hans-peter Gerber officer: Chief Scientific Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Brunilda Shtylla officer: Chief Business Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080

Venkatesh Srinivasan officer: Chief Tech Op Officer C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080

Anne Elizabeth Borgman officer: Chief Medical Officer 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705

William J Newell director, officer: CEO & President 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5

Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080

Nicki Vasquez officer: Chief Port. Strat & Alnce Ofcr C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080

Jane Chung officer: Chief Commercial Officer C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080

Trevor Hallam officer: Chief Science Officer PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512

Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850

John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301

Arturo Md Molina officer: Chief Medical Officer 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024

Linda A Fitzpatrick officer: Chief People & Comm. Officer NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085

James P Panek director C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005

Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121

Sutro Biopharma (Sutro Biopharma) Headlines

From GuruFocus

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
By Marketwired • 09-19-2023

Sutro Biopharma to Participate in Upcoming Investor Conferences
By Marketwired • 08-30-2023

Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
By Value_Insider Value_Insider • 11-08-2022

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
By Marketwired • 06-26-2023

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
By Marketwired • 08-10-2023

Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
By Value_Insider Value_Insider • 11-03-2022

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
By Stock market mentor Stock market mentor • 01-09-2023

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By sperokesalga sperokesalga • 03-17-2023

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
By Value_Insider Value_Insider • 12-10-2022

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
By Tiesvg Tiesvg • 12-20-2022

Sutro Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Liabilities	Get a 7-Day Free Trial															59.49	67.13	73.61	93.75	79.51

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	44.016	+	10.481
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	18.583	+	20.666
	=	93.7

Hans-peter Gerber	officer: Chief Scientific Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brunilda Shtylla	officer: Chief Business Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Venkatesh Srinivasan	officer: Chief Tech Op Officer	C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Anne Elizabeth Borgman	officer: Chief Medical Officer	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
William J Newell	director, officer: CEO & President	887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5
Heidi Hunter	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Nicki Vasquez	officer: Chief Port. Strat & Alnce Ofcr	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane Chung	officer: Chief Commercial Officer	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Trevor Hallam	officer: Chief Science Officer	PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jon Marc Wigginton	director	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
John Gordon Freund	director, 10 percent owner	125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Linda A Fitzpatrick	officer: Chief People & Comm. Officer	NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085
James P Panek	director	C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121